Suppr超能文献

微透析采样与局部皮肤生物等效性的临床测定

Microdialysis sampling and the clinical determination of topical dermal bioequivalence.

作者信息

McCleverty D, Lyons R, Henry B

机构信息

Pfizer Global Research & Development, Sandwich, Kent CT13 9NJ, UK.

出版信息

Int J Pharm. 2006 Feb 3;308(1-2):1-7. doi: 10.1016/j.ijpharm.2005.09.020. Epub 2005 Dec 20.

Abstract

Our objective was to determine whether the degree of variability associated with dermal microdialysis allows its practical application to determinations of bioequivalence of topically applied agents with a reasonable number of subjects. A statistical review of literature data was conducted to estimate the variances associated with subject-to-subject variability and the probe-to-probe variability within the subjects. In order to successfully utilise dermal microdialysis to establish bioequivalence of topically applied agents, particular care must be applied to study design. Due to the inherent variability between subjects, to maintain subject numbers at reasonable levels, each subject should act as their own control, thus removing the element of subject-to-subject variability from calculations of sample sizes. It is also recommended that measurements are made in duplicate in each subject to reduce the element of variability further. It is then possible to demonstrate, within 80-125% confidence limits and a subject population of approximately 20, that two formulations are bioequivalent.

摘要

我们的目标是确定与皮肤微透析相关的变异性程度是否允许其在合理数量的受试者中实际应用于局部应用制剂的生物等效性测定。对文献数据进行了统计回顾,以估计受试者之间的变异性以及受试者体内探针间的变异性相关的方差。为了成功利用皮肤微透析来确定局部应用制剂的生物等效性,必须特别注意研究设计。由于受试者之间存在固有的变异性,为了将受试者数量维持在合理水平,每个受试者应作为自身对照,从而在样本量计算中消除受试者间变异性因素。还建议在每个受试者中进行重复测量,以进一步降低变异性因素。然后有可能在80 - 125%的置信限内,在大约20名受试者的群体中证明两种制剂具有生物等效性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验